Abbott实验室达到了收益预期,提高了2026年的前景,并增加了红利。 Abbott Labs met earnings expectations, raised 2026 outlook, and increased dividend.

Abbott实验室报告,2025年的Q4收入为每股1.50美元,达到了预期水平,收入为114.6亿美元,年年增长4.4%,略低于分析师的预测。 Abbott Laboratories reported Q4 2025 earnings of $1.50 per share, meeting expectations, with $11.46 billion in revenue, a 4.4% year-over-year increase, slightly below analyst forecasts. 该公司提出了2026年的指南,预测每年的EPS为5.55至5.80美元,并宣布季度股息为每股0.63美元,收益为2.3%。 The company raised its 2026 guidance, projecting $5.55–5.80 in annual EPS, and declared a quarterly dividend of $0.63 per share, yielding 2.3%. 机构活动包括Sirios资本管理公司将股份增加33 302股,红树林伙伴公司获得6 317股。 Institutional activity included Sirios Capital Management increasing its stake by 33,302 shares and Mangrove Partners acquiring 6,317 shares. 两名执行官在3月初出售股票,而一名董事则增加了股份。 Two executives sold shares in early March, while a director boosted holdings. 分析人员维持“机动购买”共识,平均价格目标是136.16美元。 Analysts maintain a "Moderate Buy" consensus with a $136.16 average price target.